MedTrace Logo

Evaluation of Cardiovascular Risk After Preeclampsia in General Practitioners and Patients

NCT06059937 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2025-05-02

No results posted yet for this study

Summary

Pre-eclampsia is a disease characterized by placental damage leading to a cascade of complications during pregnancy. It is initially manifested by high blood pressure and the presence of albumin in the urine. It can lead to emergency hospitalization in severe cases and cause major complications or even death in the mother and the fetus.

Several studies observing the outcome of patients with pre-eclampsia have shown an increased long-term cardiovascular risk in these patients, justifying regular medical follow-up with the treating physician and specialists, mainly cardiologists.

The main objective of this research is to describe the cardiovascular risk assessment actions implemented by the treating general practitioner in the year following pre-eclampsia (blood pressure measurement in the office, self-measurement of blood pressure, ABPM, cardiological consultation, biological monitoring of blood (creatininemia, LDL, fasting glycemia) or urine (albuminurie/creatininurie ratio), and screening and management of possible smoking).

Conditions

  • Patients Hospitalized for Pre-eclampsia

Interventions

OTHER

Patient with pre-eclampsia

Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Nicolas GIRERD, MD-PhD · CHRU de NANCY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-26
Primary Completion
2025-02-11
Completion
2025-02-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06059937 on ClinicalTrials.gov